Acor­da preps FDA fil­ing af­ter Parkin­son’s drug hits the pri­ma­ry end­point in PhI­II

Acor­da’s $525 mil­lion gam­ble on a Phase III Parkin­son’s drug has paid off. The biotech $ACOR an­nounced ear­ly Thurs­day that the late-stage study of an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.